



MARYLAND MEDICAID PHARMACY PROGRAM

No. 171 (correction)
March 13, 2017

ADVISORY

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MMPP representative at 410-767-1455.

Removal of Brand Seroquel XR from DAW 6 Program

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that effective Monday, **March 27, 2017** brand Seroquel XR® **will be no longer preferred over its generic equivalents**. Claims for quetiapine fumarate extended-release tablets will be handled in the same manner as claims for other multisource drugs*. Fee-for-service Medicaid claims for brand Seroquel XR® will adjudicate only if there is prior authorization based on an approved Medwatch form which can be found at the following link:

<https://mmcp.dhmh.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

*Please note that brand and multisource of Seroquel XR® **have non-preferred status on the Preferred Drug List (PDL)**. Please refer to our website for a complete list of the PDL at the following link: <https://mmcp.dhmh.maryland.gov/pap/Documents/PDL.pdf>